nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—CYP3A4—breast cancer	0.176	1	CbGaD
Metyrapone—CYP2A6—Letrozole—breast cancer	0.119	0.212	CbGbCtD
Metyrapone—ABCC3—Fluorouracil—breast cancer	0.059	0.105	CbGbCtD
Metyrapone—CYP2A6—Tamoxifen—breast cancer	0.0355	0.063	CbGbCtD
Metyrapone—ABCC3—Doxorubicin—breast cancer	0.0336	0.0596	CbGbCtD
Metyrapone—ABCC3—Methotrexate—breast cancer	0.0325	0.0577	CbGbCtD
Metyrapone—CYP3A4—Exemestane—breast cancer	0.028	0.0498	CbGbCtD
Metyrapone—CYP2A6—Fluorouracil—breast cancer	0.0262	0.0464	CbGbCtD
Metyrapone—CYP3A4—Letrozole—breast cancer	0.0238	0.0423	CbGbCtD
Metyrapone—CYP2E1—Tamoxifen—breast cancer	0.0234	0.0416	CbGbCtD
Metyrapone—CYP2E1—Mitoxantrone—breast cancer	0.0229	0.0406	CbGbCtD
Metyrapone—CYP3A4—Anastrozole—breast cancer	0.0213	0.0377	CbGbCtD
Metyrapone—CYP3A4—Toremifene—breast cancer	0.0194	0.0345	CbGbCtD
Metyrapone—CYP3A4—Fulvestrant—breast cancer	0.0181	0.0321	CbGbCtD
Metyrapone—CYP3A4—Thiotepa—breast cancer	0.0161	0.0286	CbGbCtD
Metyrapone—CYP3A4—Ixabepilone—breast cancer	0.0147	0.0261	CbGbCtD
Metyrapone—CYP3A4—Lapatinib—breast cancer	0.0142	0.0252	CbGbCtD
Metyrapone—CYP3A4—Raloxifene—breast cancer	0.0107	0.0191	CbGbCtD
Metyrapone—CYP3A4—Vinorelbine—breast cancer	0.00787	0.014	CbGbCtD
Metyrapone—CYP3A4—Tamoxifen—breast cancer	0.0071	0.0126	CbGbCtD
Metyrapone—CYP3A4—Mitoxantrone—breast cancer	0.00693	0.0123	CbGbCtD
Metyrapone—CYP3A4—Paclitaxel—breast cancer	0.00553	0.00981	CbGbCtD
Metyrapone—CYP3A4—Irinotecan—breast cancer	0.00545	0.00968	CbGbCtD
Metyrapone—CYP3A4—Vinblastine—breast cancer	0.00485	0.0086	CbGbCtD
Metyrapone—CYP3A4—Docetaxel—breast cancer	0.004	0.00709	CbGbCtD
Metyrapone—CYP3A4—Doxorubicin—breast cancer	0.00298	0.00529	CbGbCtD
Metyrapone—Headache—Fulvestrant—breast cancer	0.000412	0.00312	CcSEcCtD
Metyrapone—Pain—Raloxifene—breast cancer	0.000412	0.00312	CcSEcCtD
Metyrapone—Pancytopenia—Mitoxantrone—breast cancer	0.000409	0.0031	CcSEcCtD
Metyrapone—Headache—Toremifene—breast cancer	0.000406	0.00308	CcSEcCtD
Metyrapone—Abdominal pain—Anastrozole—breast cancer	0.000401	0.00304	CcSEcCtD
Metyrapone—Abdominal pain—Letrozole—breast cancer	0.000401	0.00304	CcSEcCtD
Metyrapone—Dermatitis atopic—Doxorubicin—breast cancer	0.0004	0.00303	CcSEcCtD
Metyrapone—Pancytopenia—Gemcitabine—breast cancer	0.000398	0.00302	CcSEcCtD
Metyrapone—Gastrointestinal pain—Idarubicin—breast cancer	0.000394	0.00298	CcSEcCtD
Metyrapone—Gastrointestinal pain—Raloxifene—breast cancer	0.000394	0.00298	CcSEcCtD
Metyrapone—Pancytopenia—Fluorouracil—breast cancer	0.000392	0.00297	CcSEcCtD
Metyrapone—Nausea—Fulvestrant—breast cancer	0.00039	0.00296	CcSEcCtD
Metyrapone—Nausea—Toremifene—breast cancer	0.000385	0.00292	CcSEcCtD
Metyrapone—Abdominal pain—Idarubicin—breast cancer	0.000381	0.00288	CcSEcCtD
Metyrapone—Abdominal pain—Raloxifene—breast cancer	0.000381	0.00288	CcSEcCtD
Metyrapone—Angiopathy—Vinorelbine—breast cancer	0.000379	0.00287	CcSEcCtD
Metyrapone—Hypertension—Vinblastine—breast cancer	0.000378	0.00287	CcSEcCtD
Metyrapone—Dizziness—Exemestane—breast cancer	0.000378	0.00286	CcSEcCtD
Metyrapone—Alopecia—Vinorelbine—breast cancer	0.000369	0.0028	CcSEcCtD
Metyrapone—Hypertension—Tamoxifen—breast cancer	0.000367	0.00278	CcSEcCtD
Metyrapone—Vomiting—Exemestane—breast cancer	0.000363	0.00275	CcSEcCtD
Metyrapone—Angiopathy—Thiotepa—breast cancer	0.000362	0.00275	CcSEcCtD
Metyrapone—Headache—Exemestane—breast cancer	0.000358	0.00271	CcSEcCtD
Metyrapone—Dizziness—Ixabepilone—breast cancer	0.000356	0.0027	CcSEcCtD
Metyrapone—Alopecia—Thiotepa—breast cancer	0.000353	0.00267	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—breast cancer	0.000352	0.00267	CcSEcCtD
Metyrapone—Hypertension—Goserelin—breast cancer	0.000351	0.00266	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—breast cancer	0.000343	0.0026	CcSEcCtD
Metyrapone—Vomiting—Ixabepilone—breast cancer	0.000343	0.0026	CcSEcCtD
Metyrapone—Nausea—Exemestane—breast cancer	0.000339	0.00257	CcSEcCtD
Metyrapone—Headache—Ixabepilone—breast cancer	0.000337	0.00256	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Chlorambucil—breast cancer	0.000337	0.00255	CcSEcCtD
Metyrapone—Dizziness—Letrozole—breast cancer	0.000335	0.00254	CcSEcCtD
Metyrapone—Dizziness—Anastrozole—breast cancer	0.000335	0.00254	CcSEcCtD
Metyrapone—Pancytopenia—Paclitaxel—breast cancer	0.000334	0.00253	CcSEcCtD
Metyrapone—Pain—Chlorambucil—breast cancer	0.000333	0.00253	CcSEcCtD
Metyrapone—Skin disorder—Melphalan—breast cancer	0.00033	0.0025	CcSEcCtD
Metyrapone—Nervous system disorder—Goserelin—breast cancer	0.000325	0.00246	CcSEcCtD
Metyrapone—Vomiting—Letrozole—breast cancer	0.000323	0.00244	CcSEcCtD
Metyrapone—Vomiting—Anastrozole—breast cancer	0.000323	0.00244	CcSEcCtD
Metyrapone—Skin disorder—Goserelin—breast cancer	0.000322	0.00244	CcSEcCtD
Metyrapone—Nausea—Ixabepilone—breast cancer	0.00032	0.00243	CcSEcCtD
Metyrapone—Gastrointestinal pain—Chlorambucil—breast cancer	0.000319	0.00242	CcSEcCtD
Metyrapone—Dizziness—Raloxifene—breast cancer	0.000318	0.00241	CcSEcCtD
Metyrapone—Headache—Letrozole—breast cancer	0.000318	0.00241	CcSEcCtD
Metyrapone—Headache—Anastrozole—breast cancer	0.000318	0.00241	CcSEcCtD
Metyrapone—Hypotension—Melphalan—breast cancer	0.000318	0.00241	CcSEcCtD
Metyrapone—Hypertension—Vinorelbine—breast cancer	0.000314	0.00238	CcSEcCtD
Metyrapone—Angiopathy—Irinotecan—breast cancer	0.000313	0.00237	CcSEcCtD
Metyrapone—Hypotension—Goserelin—breast cancer	0.00031	0.00235	CcSEcCtD
Metyrapone—Abdominal pain—Chlorambucil—breast cancer	0.000308	0.00234	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—breast cancer	0.000308	0.00233	CcSEcCtD
Metyrapone—Vomiting—Idarubicin—breast cancer	0.000306	0.00232	CcSEcCtD
Metyrapone—Vomiting—Raloxifene—breast cancer	0.000306	0.00232	CcSEcCtD
Metyrapone—Pain—Vinblastine—breast cancer	0.000306	0.00232	CcSEcCtD
Metyrapone—Angiopathy—Gemcitabine—breast cancer	0.000305	0.00231	CcSEcCtD
Metyrapone—Alopecia—Irinotecan—breast cancer	0.000305	0.00231	CcSEcCtD
Metyrapone—Alopecia—Mitoxantrone—breast cancer	0.000305	0.00231	CcSEcCtD
Metyrapone—Headache—Raloxifene—breast cancer	0.000302	0.00229	CcSEcCtD
Metyrapone—Headache—Idarubicin—breast cancer	0.000302	0.00229	CcSEcCtD
Metyrapone—Nausea—Anastrozole—breast cancer	0.000301	0.00228	CcSEcCtD
Metyrapone—Nausea—Letrozole—breast cancer	0.000301	0.00228	CcSEcCtD
Metyrapone—Hypertension—Thiotepa—breast cancer	0.0003	0.00227	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Tamoxifen—breast cancer	0.0003	0.00227	CcSEcCtD
Metyrapone—Pain—Tamoxifen—breast cancer	0.000297	0.00225	CcSEcCtD
Metyrapone—Alopecia—Gemcitabine—breast cancer	0.000297	0.00225	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—breast cancer	0.000294	0.00223	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Melphalan—breast cancer	0.000293	0.00222	CcSEcCtD
Metyrapone—Gastrointestinal pain—Vinblastine—breast cancer	0.000292	0.00221	CcSEcCtD
Metyrapone—Alopecia—Fluorouracil—breast cancer	0.000292	0.00221	CcSEcCtD
Metyrapone—Nervous system disorder—Vinorelbine—breast cancer	0.000291	0.00221	CcSEcCtD
Metyrapone—Pain—Melphalan—breast cancer	0.000291	0.0022	CcSEcCtD
Metyrapone—Skin disorder—Vinorelbine—breast cancer	0.000288	0.00219	CcSEcCtD
Metyrapone—Nausea—Idarubicin—breast cancer	0.000286	0.00217	CcSEcCtD
Metyrapone—Nausea—Raloxifene—breast cancer	0.000286	0.00217	CcSEcCtD
Metyrapone—Gastrointestinal pain—Tamoxifen—breast cancer	0.000284	0.00215	CcSEcCtD
Metyrapone—Pain—Goserelin—breast cancer	0.000284	0.00215	CcSEcCtD
Metyrapone—Pancytopenia—Docetaxel—breast cancer	0.000283	0.00214	CcSEcCtD
Metyrapone—Abdominal pain—Vinblastine—breast cancer	0.000282	0.00214	CcSEcCtD
Metyrapone—Nervous system disorder—Thiotepa—breast cancer	0.000278	0.00211	CcSEcCtD
Metyrapone—Hypotension—Vinorelbine—breast cancer	0.000277	0.0021	CcSEcCtD
Metyrapone—Abdominal discomfort—Capecitabine—breast cancer	0.000276	0.00209	CcSEcCtD
Metyrapone—Skin disorder—Thiotepa—breast cancer	0.000275	0.00209	CcSEcCtD
Metyrapone—Abdominal pain—Tamoxifen—breast cancer	0.000274	0.00208	CcSEcCtD
Metyrapone—Pancytopenia—Capecitabine—breast cancer	0.000274	0.00207	CcSEcCtD
Metyrapone—Gastrointestinal pain—Goserelin—breast cancer	0.000271	0.00206	CcSEcCtD
Metyrapone—Abdominal pain—Goserelin—breast cancer	0.000262	0.00199	CcSEcCtD
Metyrapone—Hypertension—Mitoxantrone—breast cancer	0.000259	0.00196	CcSEcCtD
Metyrapone—Hypertension—Irinotecan—breast cancer	0.000259	0.00196	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000256	0.00194	CcSEcCtD
Metyrapone—Angiopathy—Paclitaxel—breast cancer	0.000255	0.00193	CcSEcCtD
Metyrapone—Pain—Vinorelbine—breast cancer	0.000254	0.00192	CcSEcCtD
Metyrapone—Hypertension—Gemcitabine—breast cancer	0.000252	0.00191	CcSEcCtD
Metyrapone—Alopecia—Paclitaxel—breast cancer	0.000248	0.00188	CcSEcCtD
Metyrapone—Vomiting—Chlorambucil—breast cancer	0.000248	0.00188	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—breast cancer	0.000247	0.00187	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Thiotepa—breast cancer	0.000245	0.00186	CcSEcCtD
Metyrapone—Gastrointestinal pain—Vinorelbine—breast cancer	0.000243	0.00184	CcSEcCtD
Metyrapone—Pain—Thiotepa—breast cancer	0.000243	0.00184	CcSEcCtD
Metyrapone—Nervous system disorder—Irinotecan—breast cancer	0.00024	0.00182	CcSEcCtD
Metyrapone—Skin disorder—Mitoxantrone—breast cancer	0.000238	0.0018	CcSEcCtD
Metyrapone—Dizziness—Vinblastine—breast cancer	0.000236	0.00179	CcSEcCtD
Metyrapone—Abdominal pain—Vinorelbine—breast cancer	0.000235	0.00178	CcSEcCtD
Metyrapone—Nervous system disorder—Gemcitabine—breast cancer	0.000234	0.00177	CcSEcCtD
Metyrapone—Gastrointestinal pain—Thiotepa—breast cancer	0.000232	0.00176	CcSEcCtD
Metyrapone—Skin disorder—Gemcitabine—breast cancer	0.000232	0.00176	CcSEcCtD
Metyrapone—Nausea—Chlorambucil—breast cancer	0.000232	0.00176	CcSEcCtD
Metyrapone—Nervous system disorder—Fluorouracil—breast cancer	0.00023	0.00174	CcSEcCtD
Metyrapone—Dizziness—Tamoxifen—breast cancer	0.00023	0.00174	CcSEcCtD
Metyrapone—Hypotension—Irinotecan—breast cancer	0.000229	0.00173	CcSEcCtD
Metyrapone—Hypotension—Mitoxantrone—breast cancer	0.000229	0.00173	CcSEcCtD
Metyrapone—Vomiting—Vinblastine—breast cancer	0.000227	0.00172	CcSEcCtD
Metyrapone—Abdominal pain—Thiotepa—breast cancer	0.000224	0.0017	CcSEcCtD
Metyrapone—Headache—Vinblastine—breast cancer	0.000224	0.0017	CcSEcCtD
Metyrapone—Hypotension—Gemcitabine—breast cancer	0.000223	0.00169	CcSEcCtD
Metyrapone—Vomiting—Tamoxifen—breast cancer	0.000221	0.00167	CcSEcCtD
Metyrapone—Dizziness—Goserelin—breast cancer	0.000219	0.00166	CcSEcCtD
Metyrapone—Hypotension—Fluorouracil—breast cancer	0.000219	0.00166	CcSEcCtD
Metyrapone—Headache—Tamoxifen—breast cancer	0.000217	0.00165	CcSEcCtD
Metyrapone—Angiopathy—Docetaxel—breast cancer	0.000216	0.00164	CcSEcCtD
Metyrapone—Vomiting—Melphalan—breast cancer	0.000216	0.00164	CcSEcCtD
Metyrapone—Nausea—Vinblastine—breast cancer	0.000212	0.00161	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Irinotecan—breast cancer	0.000211	0.0016	CcSEcCtD
Metyrapone—Hypertension—Paclitaxel—breast cancer	0.000211	0.0016	CcSEcCtD
Metyrapone—Vomiting—Goserelin—breast cancer	0.000211	0.0016	CcSEcCtD
Metyrapone—Alopecia—Docetaxel—breast cancer	0.000211	0.0016	CcSEcCtD
Metyrapone—Pain—Mitoxantrone—breast cancer	0.000209	0.00159	CcSEcCtD
Metyrapone—Pain—Irinotecan—breast cancer	0.000209	0.00159	CcSEcCtD
Metyrapone—Angiopathy—Capecitabine—breast cancer	0.000209	0.00159	CcSEcCtD
Metyrapone—Headache—Goserelin—breast cancer	0.000208	0.00157	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000207	0.00157	CcSEcCtD
Metyrapone—Nausea—Tamoxifen—breast cancer	0.000206	0.00156	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000206	0.00156	CcSEcCtD
Metyrapone—Abdominal discomfort—Methotrexate—breast cancer	0.000206	0.00156	CcSEcCtD
Metyrapone—Pain—Gemcitabine—breast cancer	0.000204	0.00155	CcSEcCtD
Metyrapone—Alopecia—Capecitabine—breast cancer	0.000204	0.00155	CcSEcCtD
Metyrapone—Pancytopenia—Methotrexate—breast cancer	0.000204	0.00154	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000202	0.00154	CcSEcCtD
Metyrapone—Nausea—Melphalan—breast cancer	0.000202	0.00153	CcSEcCtD
Metyrapone—Niacin—CYP2D6—breast cancer	0.000202	1	CrCbGaD
Metyrapone—Pain—Fluorouracil—breast cancer	0.000201	0.00152	CcSEcCtD
Metyrapone—Gastrointestinal pain—Mitoxantrone—breast cancer	0.0002	0.00152	CcSEcCtD
Metyrapone—Gastrointestinal pain—Irinotecan—breast cancer	0.0002	0.00152	CcSEcCtD
Metyrapone—Nausea—Goserelin—breast cancer	0.000197	0.00149	CcSEcCtD
Metyrapone—Dizziness—Vinorelbine—breast cancer	0.000196	0.00149	CcSEcCtD
Metyrapone—Nervous system disorder—Paclitaxel—breast cancer	0.000196	0.00148	CcSEcCtD
Metyrapone—Skin disorder—Paclitaxel—breast cancer	0.000194	0.00147	CcSEcCtD
Metyrapone—Abdominal pain—Mitoxantrone—breast cancer	0.000194	0.00147	CcSEcCtD
Metyrapone—Abdominal pain—Irinotecan—breast cancer	0.000194	0.00147	CcSEcCtD
Metyrapone—Pancytopenia—Epirubicin—breast cancer	0.000191	0.00145	CcSEcCtD
Metyrapone—Vomiting—Vinorelbine—breast cancer	0.000189	0.00143	CcSEcCtD
Metyrapone—Dizziness—Thiotepa—breast cancer	0.000188	0.00142	CcSEcCtD
Metyrapone—Hypotension—Paclitaxel—breast cancer	0.000187	0.00141	CcSEcCtD
Metyrapone—Headache—Vinorelbine—breast cancer	0.000186	0.00141	CcSEcCtD
Metyrapone—Vomiting—Thiotepa—breast cancer	0.00018	0.00137	CcSEcCtD
Metyrapone—Hypertension—Docetaxel—breast cancer	0.000179	0.00136	CcSEcCtD
Metyrapone—Headache—Thiotepa—breast cancer	0.000178	0.00135	CcSEcCtD
Metyrapone—Pancytopenia—Doxorubicin—breast cancer	0.000176	0.00134	CcSEcCtD
Metyrapone—Nausea—Vinorelbine—breast cancer	0.000176	0.00134	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000175	0.00133	CcSEcCtD
Metyrapone—Hypertension—Capecitabine—breast cancer	0.000173	0.00131	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000172	0.00131	CcSEcCtD
Metyrapone—Pain—Paclitaxel—breast cancer	0.000171	0.00129	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.00017	0.00129	CcSEcCtD
Metyrapone—Nausea—Thiotepa—breast cancer	0.000168	0.00128	CcSEcCtD
Metyrapone—Nervous system disorder—Docetaxel—breast cancer	0.000166	0.00126	CcSEcCtD
Metyrapone—Skin disorder—Docetaxel—breast cancer	0.000164	0.00125	CcSEcCtD
Metyrapone—Gastrointestinal pain—Paclitaxel—breast cancer	0.000163	0.00124	CcSEcCtD
Metyrapone—Dizziness—Irinotecan—breast cancer	0.000162	0.00123	CcSEcCtD
Metyrapone—Nervous system disorder—Capecitabine—breast cancer	0.000161	0.00122	CcSEcCtD
Metyrapone—Skin disorder—Capecitabine—breast cancer	0.000159	0.00121	CcSEcCtD
Metyrapone—Hypotension—Docetaxel—breast cancer	0.000158	0.0012	CcSEcCtD
Metyrapone—Abdominal pain—Paclitaxel—breast cancer	0.000158	0.0012	CcSEcCtD
Metyrapone—Angiopathy—Methotrexate—breast cancer	0.000156	0.00118	CcSEcCtD
Metyrapone—Vomiting—Mitoxantrone—breast cancer	0.000156	0.00118	CcSEcCtD
Metyrapone—Vomiting—Irinotecan—breast cancer	0.000156	0.00118	CcSEcCtD
Metyrapone—Dizziness—Fluorouracil—breast cancer	0.000155	0.00118	CcSEcCtD
Metyrapone—Headache—Mitoxantrone—breast cancer	0.000153	0.00116	CcSEcCtD
Metyrapone—Headache—Irinotecan—breast cancer	0.000153	0.00116	CcSEcCtD
Metyrapone—Hypotension—Capecitabine—breast cancer	0.000153	0.00116	CcSEcCtD
Metyrapone—Alopecia—Methotrexate—breast cancer	0.000152	0.00115	CcSEcCtD
Metyrapone—Vomiting—Gemcitabine—breast cancer	0.000152	0.00115	CcSEcCtD
Metyrapone—Headache—Gemcitabine—breast cancer	0.000149	0.00113	CcSEcCtD
Metyrapone—Vomiting—Fluorouracil—breast cancer	0.000149	0.00113	CcSEcCtD
Metyrapone—Headache—Fluorouracil—breast cancer	0.000147	0.00111	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Docetaxel—breast cancer	0.000146	0.00111	CcSEcCtD
Metyrapone—Angiopathy—Epirubicin—breast cancer	0.000146	0.00111	CcSEcCtD
Metyrapone—Nausea—Mitoxantrone—breast cancer	0.000145	0.0011	CcSEcCtD
Metyrapone—Nausea—Irinotecan—breast cancer	0.000145	0.0011	CcSEcCtD
Metyrapone—Pain—Docetaxel—breast cancer	0.000145	0.0011	CcSEcCtD
Metyrapone—Alopecia—Epirubicin—breast cancer	0.000142	0.00108	CcSEcCtD
Metyrapone—Nausea—Gemcitabine—breast cancer	0.000142	0.00107	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Capecitabine—breast cancer	0.000142	0.00107	CcSEcCtD
Metyrapone—Pain—Capecitabine—breast cancer	0.00014	0.00106	CcSEcCtD
Metyrapone—Nausea—Fluorouracil—breast cancer	0.000139	0.00106	CcSEcCtD
Metyrapone—Gastrointestinal pain—Docetaxel—breast cancer	0.000138	0.00105	CcSEcCtD
Metyrapone—Angiopathy—Doxorubicin—breast cancer	0.000135	0.00102	CcSEcCtD
Metyrapone—Gastrointestinal pain—Capecitabine—breast cancer	0.000134	0.00102	CcSEcCtD
Metyrapone—Abdominal pain—Docetaxel—breast cancer	0.000134	0.00101	CcSEcCtD
Metyrapone—Dizziness—Paclitaxel—breast cancer	0.000132	0.001	CcSEcCtD
Metyrapone—Alopecia—Doxorubicin—breast cancer	0.000131	0.000996	CcSEcCtD
Metyrapone—Abdominal pain—Capecitabine—breast cancer	0.00013	0.000982	CcSEcCtD
Metyrapone—Vomiting—Paclitaxel—breast cancer	0.000127	0.000963	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000126	0.000958	CcSEcCtD
Metyrapone—Headache—Paclitaxel—breast cancer	0.000125	0.000948	CcSEcCtD
Metyrapone—Hypertension—Epirubicin—breast cancer	0.000121	0.000916	CcSEcCtD
Metyrapone—Nervous system disorder—Methotrexate—breast cancer	0.00012	0.000907	CcSEcCtD
Metyrapone—Nausea—Paclitaxel—breast cancer	0.000119	0.000899	CcSEcCtD
Metyrapone—Skin disorder—Methotrexate—breast cancer	0.000119	0.000898	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000118	0.000897	CcSEcCtD
Metyrapone—Hypotension—Methotrexate—breast cancer	0.000114	0.000864	CcSEcCtD
Metyrapone—Nervous system disorder—Epirubicin—breast cancer	0.000112	0.000849	CcSEcCtD
Metyrapone—Dizziness—Docetaxel—breast cancer	0.000112	0.000849	CcSEcCtD
Metyrapone—Hypertension—Doxorubicin—breast cancer	0.000112	0.000847	CcSEcCtD
Metyrapone—Skin disorder—Epirubicin—breast cancer	0.000111	0.000841	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000109	0.00083	CcSEcCtD
Metyrapone—Dizziness—Capecitabine—breast cancer	0.000108	0.000822	CcSEcCtD
Metyrapone—Vomiting—Docetaxel—breast cancer	0.000108	0.000816	CcSEcCtD
Metyrapone—Hypotension—Epirubicin—breast cancer	0.000107	0.000809	CcSEcCtD
Metyrapone—Headache—Docetaxel—breast cancer	0.000106	0.000804	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Methotrexate—breast cancer	0.000105	0.000799	CcSEcCtD
Metyrapone—Pain—Methotrexate—breast cancer	0.000104	0.000791	CcSEcCtD
Metyrapone—Vomiting—Capecitabine—breast cancer	0.000104	0.00079	CcSEcCtD
Metyrapone—Nervous system disorder—Doxorubicin—breast cancer	0.000104	0.000785	CcSEcCtD
Metyrapone—Headache—Capecitabine—breast cancer	0.000103	0.000778	CcSEcCtD
Metyrapone—Skin disorder—Doxorubicin—breast cancer	0.000103	0.000778	CcSEcCtD
Metyrapone—Nausea—Docetaxel—breast cancer	0.000101	0.000762	CcSEcCtD
Metyrapone—Gastrointestinal pain—Methotrexate—breast cancer	9.98e-05	0.000756	CcSEcCtD
Metyrapone—Hypotension—Doxorubicin—breast cancer	9.87e-05	0.000748	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Epirubicin—breast cancer	9.86e-05	0.000747	CcSEcCtD
Metyrapone—Pain—Epirubicin—breast cancer	9.76e-05	0.00074	CcSEcCtD
Metyrapone—Nausea—Capecitabine—breast cancer	9.74e-05	0.000738	CcSEcCtD
Metyrapone—Abdominal pain—Methotrexate—breast cancer	9.65e-05	0.000731	CcSEcCtD
Metyrapone—Gastrointestinal pain—Epirubicin—breast cancer	9.34e-05	0.000708	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Doxorubicin—breast cancer	9.12e-05	0.000691	CcSEcCtD
Metyrapone—Pain—Doxorubicin—breast cancer	9.04e-05	0.000685	CcSEcCtD
Metyrapone—Abdominal pain—Epirubicin—breast cancer	9.03e-05	0.000684	CcSEcCtD
Metyrapone—Gastrointestinal pain—Doxorubicin—breast cancer	8.64e-05	0.000655	CcSEcCtD
Metyrapone—Abdominal pain—Doxorubicin—breast cancer	8.35e-05	0.000633	CcSEcCtD
Metyrapone—Dizziness—Methotrexate—breast cancer	8.07e-05	0.000612	CcSEcCtD
Metyrapone—Vomiting—Methotrexate—breast cancer	7.76e-05	0.000588	CcSEcCtD
Metyrapone—Headache—Methotrexate—breast cancer	7.64e-05	0.000579	CcSEcCtD
Metyrapone—Dizziness—Epirubicin—breast cancer	7.55e-05	0.000572	CcSEcCtD
Metyrapone—Vomiting—Epirubicin—breast cancer	7.26e-05	0.00055	CcSEcCtD
Metyrapone—Nausea—Methotrexate—breast cancer	7.25e-05	0.000549	CcSEcCtD
Metyrapone—Headache—Epirubicin—breast cancer	7.15e-05	0.000542	CcSEcCtD
Metyrapone—Dizziness—Doxorubicin—breast cancer	6.99e-05	0.00053	CcSEcCtD
Metyrapone—Nausea—Epirubicin—breast cancer	6.78e-05	0.000514	CcSEcCtD
Metyrapone—Vomiting—Doxorubicin—breast cancer	6.72e-05	0.000509	CcSEcCtD
Metyrapone—Headache—Doxorubicin—breast cancer	6.62e-05	0.000502	CcSEcCtD
Metyrapone—Nausea—Doxorubicin—breast cancer	6.28e-05	0.000476	CcSEcCtD
Metyrapone—ABCC3—Metabolism—HSP90AA1—breast cancer	1.42e-05	0.000111	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CG—breast cancer	1.39e-05	0.000108	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NCOA1—breast cancer	1.38e-05	0.000108	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCC1—breast cancer	1.37e-05	0.000107	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA3—breast cancer	1.37e-05	0.000107	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HMMR—breast cancer	1.37e-05	0.000107	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP19A1—breast cancer	1.36e-05	0.000106	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—STK11—breast cancer	1.36e-05	0.000106	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPARGC1B—breast cancer	1.32e-05	0.000103	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CAV1—breast cancer	1.31e-05	0.000102	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—DPYD—breast cancer	1.29e-05	0.000101	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MED12—breast cancer	1.29e-05	0.000101	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.28e-05	9.98e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ALDOA—breast cancer	1.27e-05	9.9e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—COMT—breast cancer	1.27e-05	9.89e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTP1—breast cancer	1.26e-05	9.84e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.25e-05	9.78e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CA9—breast cancer	1.25e-05	9.75e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA4—breast cancer	1.25e-05	9.75e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—HMOX1—breast cancer	1.24e-05	9.7e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ITPR1—breast cancer	1.24e-05	9.68e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA3—breast cancer	1.23e-05	9.61e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC2A2—breast cancer	1.22e-05	9.54e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CD—breast cancer	1.22e-05	9.51e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA2—breast cancer	1.22e-05	9.5e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPX2—breast cancer	1.22e-05	9.5e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ALB—breast cancer	1.2e-05	9.39e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPX4—breast cancer	1.2e-05	9.38e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SULT1A1—breast cancer	1.2e-05	9.38e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ABCG2—breast cancer	1.2e-05	9.35e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CPT1A—breast cancer	1.2e-05	9.35e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MTR—breast cancer	1.2e-05	9.35e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CG—breast cancer	1.19e-05	9.32e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ABCB1—breast cancer	1.19e-05	9.31e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SYNJ2—breast cancer	1.19e-05	9.26e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HPGDS—breast cancer	1.17e-05	9.17e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—IDH1—breast cancer	1.17e-05	9.17e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTA1—breast cancer	1.17e-05	9.17e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—TYMS—breast cancer	1.17e-05	9.15e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HBA1—breast cancer	1.17e-05	9.11e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NAT2—breast cancer	1.16e-05	9.06e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PLA2G4A—breast cancer	1.16e-05	9.04e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTM1—breast cancer	1.16e-05	9.04e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NCOR1—breast cancer	1.16e-05	9.04e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—NOS3—breast cancer	1.15e-05	8.98e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTT1—breast cancer	1.14e-05	8.89e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ACHE—breast cancer	1.14e-05	8.89e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GPX1—breast cancer	1.11e-05	8.66e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NDUFS3—breast cancer	1.1e-05	8.61e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP1A1—breast cancer	1.1e-05	8.57e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ERCC2—breast cancer	1.09e-05	8.5e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP17A1—breast cancer	1.08e-05	8.42e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS1—breast cancer	1.07e-05	8.33e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ENO1—breast cancer	1.07e-05	8.33e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CB—breast cancer	1.06e-05	8.29e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS2—breast cancer	1.05e-05	8.22e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CD—breast cancer	1.05e-05	8.2e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP2D6—breast cancer	1.05e-05	8.17e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CHST9—breast cancer	1.04e-05	8.1e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ALB—breast cancer	1.04e-05	8.09e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA2—breast cancer	1.03e-05	8.02e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—MTHFR—breast cancer	1.02e-05	7.99e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MED12—breast cancer	1.02e-05	7.95e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—DPYD—breast cancer	1.02e-05	7.95e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ALDOA—breast cancer	1e-05	7.82e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—FASN—breast cancer	9.96e-06	7.78e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—BCHE—breast cancer	9.92e-06	7.75e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—NOS3—breast cancer	9.91e-06	7.74e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—COX11—breast cancer	9.83e-06	7.67e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC5A5—breast cancer	9.8e-06	7.65e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA3—breast cancer	9.73e-06	7.6e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC2A2—breast cancer	9.66e-06	7.54e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC2A1—breast cancer	9.46e-06	7.39e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NQO1—breast cancer	9.46e-06	7.39e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CPT1A—breast cancer	9.46e-06	7.39e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MTR—breast cancer	9.46e-06	7.39e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCG2—breast cancer	9.46e-06	7.39e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CAV1—breast cancer	9.44e-06	7.37e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HPGDS—breast cancer	9.28e-06	7.25e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP3A4—breast cancer	9.23e-06	7.21e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HBA1—breast cancer	9.22e-06	7.2e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTEN—breast cancer	9.18e-06	7.16e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CB—breast cancer	9.15e-06	7.15e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP1B1—breast cancer	9.07e-06	7.09e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS2—breast cancer	9.07e-06	7.08e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	9.02e-06	7.04e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ACHE—breast cancer	9e-06	7.03e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTT1—breast cancer	9e-06	7.03e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CDA—breast cancer	8.99e-06	7.02e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SHMT1—breast cancer	8.99e-06	7.02e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HSP90AA1—breast cancer	8.9e-06	6.95e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOA1—breast cancer	8.66e-06	6.76e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLCO1B1—breast cancer	8.65e-06	6.76e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC2A5—breast cancer	8.65e-06	6.76e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CG—breast cancer	8.6e-06	6.71e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP19A1—breast cancer	8.53e-06	6.66e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—STK11—breast cancer	8.53e-06	6.66e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP17A1—breast cancer	8.52e-06	6.65e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ENO1—breast cancer	8.43e-06	6.59e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS1—breast cancer	8.43e-06	6.59e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—APRT—breast cancer	8.36e-06	6.53e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP2D6—breast cancer	8.27e-06	6.46e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA2—breast cancer	8.12e-06	6.34e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—COMT—breast cancer	7.93e-06	6.19e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTEN—breast cancer	7.91e-06	6.17e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTP1—breast cancer	7.89e-06	6.16e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—FASN—breast cancer	7.87e-06	6.15e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ESRRA—breast cancer	7.86e-06	6.14e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ANGPTL4—breast cancer	7.86e-06	6.14e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—BCHE—breast cancer	7.84e-06	6.12e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—HMOX1—breast cancer	7.79e-06	6.08e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ITPR1—breast cancer	7.77e-06	6.07e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC5A5—breast cancer	7.74e-06	6.05e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CD—breast cancer	7.56e-06	5.9e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NQO1—breast cancer	7.48e-06	5.84e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC2A1—breast cancer	7.48e-06	5.84e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ABCB1—breast cancer	7.47e-06	5.83e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ALB—breast cancer	7.46e-06	5.83e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HADHB—breast cancer	7.45e-06	5.82e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPI—breast cancer	7.45e-06	5.82e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—TYMS—breast cancer	7.34e-06	5.73e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP3A4—breast cancer	7.29e-06	5.7e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NCOR1—breast cancer	7.25e-06	5.66e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTM1—breast cancer	7.25e-06	5.66e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PLA2G4A—breast cancer	7.25e-06	5.66e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP1B1—breast cancer	7.17e-06	5.6e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—NOS3—breast cancer	7.14e-06	5.57e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALDH7A1—breast cancer	7.11e-06	5.55e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALDH1A1—breast cancer	7.11e-06	5.55e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HSP90AA1—breast cancer	7.03e-06	5.49e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GPX1—breast cancer	6.95e-06	5.42e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP1A1—breast cancer	6.88e-06	5.37e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOA1—breast cancer	6.84e-06	5.34e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ERCC2—breast cancer	6.82e-06	5.33e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NME1—breast cancer	6.81e-06	5.32e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ADSL—breast cancer	6.81e-06	5.32e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—UMPS—breast cancer	6.81e-06	5.32e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PHGDH—breast cancer	6.81e-06	5.32e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—FHL2—breast cancer	6.81e-06	5.32e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—STK11—breast cancer	6.74e-06	5.26e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP19A1—breast cancer	6.74e-06	5.26e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HPSE—breast cancer	6.68e-06	5.22e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—BRIP1—breast cancer	6.68e-06	5.22e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—LDHB—breast cancer	6.68e-06	5.22e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CB—breast cancer	6.59e-06	5.15e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS2—breast cancer	6.53e-06	5.1e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CA—breast cancer	6.47e-06	5.05e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—MTHFR—breast cancer	6.41e-06	5.01e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA3—breast cancer	6.33e-06	4.95e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HMMR—breast cancer	6.33e-06	4.95e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCC1—breast cancer	6.33e-06	4.95e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—COMT—breast cancer	6.27e-06	4.89e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTP1—breast cancer	6.24e-06	4.87e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—HMOX1—breast cancer	6.15e-06	4.8e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ITPR1—breast cancer	6.14e-06	4.79e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPARGC1B—breast cancer	6.13e-06	4.79e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CAV1—breast cancer	5.91e-06	4.62e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCB1—breast cancer	5.91e-06	4.61e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—TYMS—breast cancer	5.8e-06	4.53e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CA9—breast cancer	5.79e-06	4.52e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA4—breast cancer	5.79e-06	4.52e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PLA2G4A—breast cancer	5.73e-06	4.48e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NCOR1—breast cancer	5.73e-06	4.48e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTM1—breast cancer	5.73e-06	4.48e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTEN—breast cancer	5.69e-06	4.45e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA2—breast cancer	5.65e-06	4.41e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPX2—breast cancer	5.65e-06	4.41e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CA—breast cancer	5.58e-06	4.36e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SULT1A1—breast cancer	5.58e-06	4.35e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPX4—breast cancer	5.58e-06	4.35e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPX1—breast cancer	5.49e-06	4.29e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—IDH1—breast cancer	5.45e-06	4.25e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTA1—breast cancer	5.45e-06	4.25e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP1A1—breast cancer	5.43e-06	4.24e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ERCC2—breast cancer	5.39e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CG—breast cancer	5.39e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NAT2—breast cancer	5.39e-06	4.21e-05	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—AKT1—breast cancer	5.29e-06	4.13e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—MTHFR—breast cancer	5.07e-06	3.96e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CD—breast cancer	4.74e-06	3.7e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MED12—breast cancer	4.72e-06	3.69e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—DPYD—breast cancer	4.72e-06	3.69e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ALB—breast cancer	4.67e-06	3.65e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CAV1—breast cancer	4.67e-06	3.65e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALDOA—breast cancer	4.65e-06	3.63e-05	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—AKT1—breast cancer	4.56e-06	3.56e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA3—breast cancer	4.51e-06	3.52e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC2A2—breast cancer	4.48e-06	3.5e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—NOS3—breast cancer	4.47e-06	3.49e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCG2—breast cancer	4.39e-06	3.43e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CPT1A—breast cancer	4.39e-06	3.43e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MTR—breast cancer	4.39e-06	3.43e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HPGDS—breast cancer	4.31e-06	3.36e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HBA1—breast cancer	4.28e-06	3.34e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CG—breast cancer	4.26e-06	3.32e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTT1—breast cancer	4.18e-06	3.26e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ACHE—breast cancer	4.18e-06	3.26e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CB—breast cancer	4.13e-06	3.22e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS2—breast cancer	4.09e-06	3.19e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CA—breast cancer	4.02e-06	3.14e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP17A1—breast cancer	3.95e-06	3.09e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS1—breast cancer	3.91e-06	3.06e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ENO1—breast cancer	3.91e-06	3.06e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP2D6—breast cancer	3.84e-06	3e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA2—breast cancer	3.77e-06	2.94e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CD—breast cancer	3.74e-06	2.92e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ALB—breast cancer	3.69e-06	2.88e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—FASN—breast cancer	3.65e-06	2.85e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—BCHE—breast cancer	3.64e-06	2.84e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC5A5—breast cancer	3.59e-06	2.81e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTEN—breast cancer	3.57e-06	2.78e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—NOS3—breast cancer	3.53e-06	2.76e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC2A1—breast cancer	3.47e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NQO1—breast cancer	3.47e-06	2.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP1B1—breast cancer	3.33e-06	2.6e-05	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—AKT1—breast cancer	3.28e-06	2.56e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HSP90AA1—breast cancer	3.26e-06	2.55e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CB—breast cancer	3.26e-06	2.55e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS2—breast cancer	3.23e-06	2.52e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOA1—breast cancer	3.17e-06	2.48e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—STK11—breast cancer	3.13e-06	2.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP19A1—breast cancer	3.13e-06	2.44e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—COMT—breast cancer	2.91e-06	2.27e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTP1—breast cancer	2.89e-06	2.26e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—HMOX1—breast cancer	2.85e-06	2.23e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ITPR1—breast cancer	2.85e-06	2.22e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTEN—breast cancer	2.82e-06	2.2e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCB1—breast cancer	2.74e-06	2.14e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—TYMS—breast cancer	2.69e-06	2.1e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NCOR1—breast cancer	2.66e-06	2.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTM1—breast cancer	2.66e-06	2.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.66e-06	2.08e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPX1—breast cancer	2.55e-06	1.99e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP1A1—breast cancer	2.52e-06	1.97e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CA—breast cancer	2.52e-06	1.96e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ERCC2—breast cancer	2.5e-06	1.95e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—MTHFR—breast cancer	2.35e-06	1.84e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CAV1—breast cancer	2.17e-06	1.69e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—AKT1—breast cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CA—breast cancer	1.99e-06	1.55e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CG—breast cancer	1.97e-06	1.54e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CD—breast cancer	1.74e-06	1.36e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALB—breast cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—NOS3—breast cancer	1.64e-06	1.28e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—AKT1—breast cancer	1.62e-06	1.27e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CB—breast cancer	1.51e-06	1.18e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS2—breast cancer	1.5e-06	1.17e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTEN—breast cancer	1.31e-06	1.02e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CA—breast cancer	9.23e-07	7.2e-06	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—AKT1—breast cancer	7.54e-07	5.88e-06	CbGpPWpGaD
